3D-pharmacophore model based virtual screening to identify dual-binding site and selective acetylcholinesterase inhibitors

Medicinal Chemistry Research

Volumn 20, Issue 9, 2011, Pages 1422-1430

  Gupta, Shikhar ^a   Mohan, C Gopi ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Acetylcholinesterase inhibitors; Alzheimer's disease; Dual binding site; Pharmacophore modelling; Virtual screening

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE INHIBITOR;

BLOOD BRAIN BARRIER; CONFERENCE PAPER; DRUG BINDING SITE; MOLECULAR DOCKING; MOLECULAR MODEL; PHARMACOPHORE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; TOXICITY TESTING; VIRTUAL REALITY;

EID: 84856212958     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-010-9373-7     Document Type: Conference Paper

References (29)

1. Accelrys (2009) Accelrys Discovery Studio 2.5. Accelrys, San Diego. www.accelrys.com
2. Alavijeh MS, Chishty M, Qaiser MZ, Palmer AM (2005) Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery. NeuroRx 2:554-571 (Pubitemid 41393265)
3. Belluti F, Rampa A, Piazzi L, Bisi A, Gobbi S, Bartolini M (2005) Cholinesterase inhibitors: Xanthostigmine derivatives blocking the acetylcholinesterase-induced-amyloid aggregation. J Med Chem 48:4444-4456 (Pubitemid 40884946)
4. Bharatham N, Bharatham K, Lee KW (2007) Pharmacophore identification and virtual screening for methionyl-tRNA synthetase inhibitors. J Mol Graph Model 25:813-823 (Pubitemid 46216116)
5. BioSolveIT GmbH (2008) FlexX version 3.1.1. BioSolveIT GmbH, Germany
6. Butters N, Delis DC, Lucas JA (1995) Clinical assessment of memory disorders in amnesia and dementia. Annu Rev Psychol 46:493-523
7. Campiani G, Fattorusso C, Butini S, Gaeta A, Agnusdei M, Gemma S, Persico M, Catalanotti B, Savini L, Nacci V, Novellino E, Holloway HW, Greig NH, Belinskaya T, Fedorko JM, Saxena A (2005) Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors. J Med Chem 48:1919-1929 (Pubitemid 40396322)
8. Clark M, Cramer RD, Van ON (1989) Validation of the general purpose tripos 5.2 force field. J Comput Chem 10:982-1012
9. Debnath AK (2002) Pharmacophore mapping of a series of 2,4-diamino-5-deazapteridine inhibitors of mycobacterium avium complex dihydrofolate reductase. J Med Chem 45:41-53 (Pubitemid 34038541)
10. Fletcher R, Powell MJD (1963) A rapidly convergent descent method for minimization. Comput J 6:163-168
11. Gasteiger J, Marsili M (1980) Iterative partial equalization of orbital electronegativity-a rapid access to atomic charges. Tetrahedron 36:3219-3228
12. Giacobini E (2004) Cholinesterase inhibitors: New roles and therapeutic alternatives. Pharmacol Res 50:433-440 (Pubitemid 39078534)
13. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297:353-356 (Pubitemid 34790756)
14. Houghton PJ, Ren Y, Howes MJ (2006) Acetylcholinesterase inhibitors from plants and fungi. Nat Prod Rep 23:181-199
15. Inestrosa NC, Dinamarca MC, Alvarez A, Center CB (2008) Amyloid-cholinesterase interactions. FEBS J. 275:625-632
16. Kryger G, Silman I, Sussman JL (1999) Structure of acetylcholinesterase complexed with E2020 (Aricept®): Implications for the design of new anti-Alzheimer drugs. Structure 7:297-307 (Pubitemid 29159689)
17. Lane RM, Potkin SG, Enz A (2005) Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Int J Neuropsychopharmacol 9:101-124 (Pubitemid 43068340)
18. Lipinski CA (2000) Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 44:235-249 (Pubitemid 32239479)
19. Lockridge O, Masson P (2000) Pesticides and susceptible populations: People with butyrylcholinesterase genetic variants may be at risk. Neurotoxicology 21:113-126 (Pubitemid 30228241)
20. MacDougall IJA, Griffith R (2008) Pharmacophore design and database searching for selective monoamine neurotransmitter transporter ligands. J Mol Graph Model 26:1113-1124 (Pubitemid 351374850)
21. Mizutani MY, Itai A (2004) Efficient method for high-throughput virtual screening based on flexible docking: Discovery of novel acetylcholinesterase inhibitors. J Med Chem 47:4818-4828 (Pubitemid 39238256)
22. Nicolet Y, Lockridge O, Masson P, Fontecilla-Camps JC, Nachon F (2003) Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products. J Biol Chem 278:41141-41147 (Pubitemid 37280939)
23. Oprea TI, Matter H (2004) Integrating virtual screening in lead discovery. Curr Opin Chem Biol 8:349-358 (Pubitemid 38996798)
24. Piazzi L, Belluti F, Bisi A, Gobbi S, Rizzo S, Bartolini M, Andrisano V, Recanatini M, Rampa A (2007) Cholinesterase inhibitors: SAR and enzyme inhibitory activity of 3-[x-(benzylmethylamino) alkoxy]xanthen-9-ones. Bioorg Med Chem 15:575-585 (Pubitemid 44738548)
25. Rampa A, Bisi A, Valenti P, Recanatini M, Cavalli A, Andrisano V, Cavrini V, Fin L, Buriani A, Giusti P (1998) Acetylcholinesterase inhibitors: Synthesis and structure-activity relationships of x-[N-Methyl-N-(3-alkylcarbamoyl oxy phenyl)-methyl] aminoalkoxy heteroaryl derivatives. J Med Chem 41:3976-3986 (Pubitemid 28483475)
26. Rampa A, Piazzi L, Belluti F, Gobbi S, Bisi A, Bartolini M, Andrisano V, Cavrini V, Cavalli A, Recanatini M (2001) Acetylcholinesterase inhibitors: SAR and kinetic studies on x-[N-methyl-N-(3-alkylcarbamoyloxyphenyl)methyl] aminoalkoxy aryl derivatives. J Med Chem 44:3810-3820 (Pubitemid 33051473)
27. Sanderson DM, Earnshaw CG (1991) Computer prediction of possible toxic action from chemical structure; the DEREK system. Hum Exp Toxicol 10:261-273
28. Tripos Associates Inc. (2005) Molecular Modeling Software, version 7.1. Tripos Associates Inc., Missouri
29. Wing LK, Behanna HA, Van Eldik LJ, Watterson M, Ranaivo R (2006) De novo and molecular target-independent discovery of orally bioavailable lead compounds for neurological disorders. Curr Alzheimer Res 3:205-214 (Pubitemid 43988133)